Dupilumab for atopic dermatitis treatment: A single-center retrospective study
Yıl: 2022 Cilt: 56 Sayı: 1 Sayfa Aralığı: 12 - 16 Metin Dili: İngilizce DOI: 0.4274/turkderm.galenos.2021.36604 İndeks Tarihi: 16-06-2022
Dupilumab for atopic dermatitis treatment: A single-center retrospective study
Öz: Background and Design: Atopic dermatitis (AD) is a common chronic, recurrent, and itchy inflammatory skin disease. Various therapeutic
agents are available, but severe side effects may limit their usage. Recently, dupilumab, a human monoclonal antibody that targets the
interleukin-4 (IL-4) receptor alpha subunit of heterodimeric IL-4 and IL-13 receptors, is approved and might be used in patients with resistant
AD, with the permission of the Ministry of Health.
Materials and Methods: This study aimed to retrospectively evaluate the clinical characteristics of patients and dupilumab treatment
responses in our center. This study included patients with AD who were unresponsive to conventional treatments and treated with dupilumab.
Sociodemographic, laboratory data, previous treatments, and responses along with disease severity scores [eczema area and severity index
(EASI)] before and after dupilumab were evaluated through the electronic files of patients.
Results: A total of 21 patients (13 males and 8 females) between June 2019 and March 2021 were identified. The mean age of patients was
40.57±15.21 years. The mean duration of dupilumab treatment was 6.59±5.88 months. The mean EASI score at the beginning of dupilumab
was 15.35±8.03, whereas 4.6±2.9 after treatment. A 70-100% improvement was found in approximately 75% of the patients. No side effects
were observed that required treatment discontinuation or dose changes.
Conclusion: Our study has the highest number of reported patients in our country, which revealed that dupilumab is highly effective and safe
for conventional treatment-resistant
Anahtar Kelime: Atopik dermatit tedavisinde dupilumab: Tek merkezli retrospektif çalışma
Öz: Amaç: Atopik dermatit (AD) sık görülen kronik, tekrarlayıcı, kaşıntılı, inflamatuvar bir deri hastalığıdır. Tedavisinde çeşitli tedavi ajanları bulunsa
da bu ajanların ciddi yan etkileri kullanımlarını sınırlamaktadır. Son zamanlarda, interlökin-4 (IL-4) ve IL-13 reseptörlerinin IL-4 reseptör alfa alt
birimini hedefleyen heterodimerik bir insan monoklonal antikoru olan dupilumab onay almıştır ve dirençli AD’li hastalarda Sağlık Bakanlığı izni
ile kullanılabilmektedir.
Gereç ve Yöntem: Bu çalışmada hastalarımızın klinik özelliklerini ve dupilumab tedavi yanıtlarını retrospektif olarak değerlendirmeyi amaçladık.
Konvansiyonel tedavilere yanıt vermeyen ve dupilumab başlanan AD’li hastalar çalışmaya dahil edildi. Hastaların sosyodemografik ve laboratuvar
verileri, önceki tedavileri ve dupilumab tedavi öncesi ve sonrasındaki hastalık şiddet skorları [egzama alan ve şiddet indeksi (EAŞİ)] ve tedavi
yanıtları değerlendirildi.
Bulgular: Haziran 2019 ile Mart 2021 arasında takip edilen toplam 21 hasta (13 erkek, 8 kadın) saptandı. Hastaların ortalama yaşı 40,57±15,21
yıldı. Ortalama dupilumab tedavi süresi 6,59±5,88 aydı. Dupilumab başlangıcındaki ortalama EAŞİ skoru 15,35±8,03 iken, tedavi sonrası
ortalama EAŞİ skoru 4,6±2,9 olarak saptandı. Hastaların yaklaşık %75’inde %70-100 aralığında bir iyileşme saptandı. Tedavinin kesilmesini veya
doz değişikliğini gerektiren hiçbir yan etki gözlenmedi.
Sonuç: Ülkemizden bildirilen en yüksek hasta sayısına sahip olan çalışmamızda, dupilumabın geleneksel tedavilere dirençli AD’de oldukça etkili
ve güvenli bir seçenek olduğu saptanmış
Anahtar Kelime: Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
- 1. Silverberg JI, Guttman-Yassky E, Gadkari A, et al.: Real-world persistence with dupilumab among adults with atopic dermatitis. Ann Allergy Asthma Immunol 2021;126:40-5.
- 2. Silverberg JI, Hanifin JM: Adult eczema prevalence and associations with asthma and other health and demographic factors: a US population-based study. J Allergy Clin Immunol 2013;132:1132-8.
- 3. Barbarot S, Auziere S, Gadkari A, et al.: Epidemiology of atopic dermatitis in adults: Results from an international survey. Allergy 2018;73:1284-93.
- 4. Weidinger S, Novak N: Atopic dermatitis. Lancet 2016;387:1109-22.
- 5. Bieber T: Atopic dermatitis. Ann Dermatol 2010;22:125-37.
- 6. Ertam I, Su Ö, Alper S, et al.: The Turkish guideline for the diagnosis and management of atopic dermatitis-2018. Turkderm-Turk Arch Dermatol Venereology 2018;52:6-23.
- 7. Simpson EL, Bieber T, Guttman-Yassky E, et al.: Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med 2016;375:2335- 48.
- 8. Tofte SJ, Graeber M, Cherill R, Omoto M, Thurston M, Hanifin JM: Eczema area and severity index (EASI): A new tool to evaluate atopic dermatitis. J Eur Acad Dermatol Venereol 1998;11:S197.
- 9. Blauvelt A, de Bruin-Weller M, Gooderham M, et al.: Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): A 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet 2017;389:2287- 2303.
- 10. Askin O, Yucesoy SN, Serdaroglu S: The evaluation of dupilumab treatment response in atopic dermatitis patients. North Clin Istanb 2021;8:145-9.
- 11. Ferrucci S, Casazza G, Angileri L, et al.: Clinical response and quality of life in patients with severe atopic dermatitis treated with dupilumab: A single- center real-life experience. J Clin Med 2020;9:791.
- 12. Jang DH, Heo SJ, Jung HJ, Park MY, Seo SJ, Ahn J: Retrospective study of dupilumab treatment for moderate to severe atopic dermatitis in Korea: Efficacy and safety of dupilumab in real-world practice. J Clin Med 2020;9:1982.
- 13. Nettis E, Ferrucci SM, Ortoncelli M, et al.: Use of dupilumab for 543 adult patients with moderate-to-severe atopic dermatitis: A multicenter, retrospective study. J Investig Allergol Clin Immunol 2020. DOI: 10.18176/ jiaci.0641. Epub ahead of print.
- 14. Napolitano M, Fabbrocini G, Scalvenzi M, Blasio C, Stingeni L, Patruno C: Efficacy and safety of dupilumab in atopic dermatitis in elderly patients: a retrospective study. Clin Exp Dermatol 2020;45:888-90.
- 15. Patruno C, Napolitano M, Argenziano G, et al.: DADE - Dupilumab for Atopic Dermatitis of the Elderly Study group. Dupilumab therapy of atopic dermatitis of the elderly: A multicentre, real-life study. J Eur Acad Dermatol Venereol 2021;35:958-64.
- 16. Paller AS, Siegfried EC, Thaçi D, et al.: Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: A randomized, double-blinded, placebo-controlled phase 3 trial. J Am Acad Dermatol 2020;83:1282-93.
- 17. Mennini M, Dahdah L, Fiocchi A: Two phase 3 Trials of Dupilumab versus placebo in atopic dermatitis. N Engl J Med 2017;376:1090.
- 18. Nahum Y, Mimouni M, Livny E, Bahar I, Hodak E, Leshem YA: Dupilumab- induced ocular surface disease (DIOSD) in patients with atopic dermatitis: Clinical presentation, risk factors for development and outcomes of treatment with tacrolimus ointment. Br J Ophthalmol 2020;104:776-9.
- 19. Ou Z, Chen C, Chen A, Yang Y, Zhou W: Adverse events of dupilumab in adults with moderate-tosevere atopic dermatitis: a meta-analysis. Int Immunopharmacol 2018;54:303-10.
- 20. Akinlade B, Guttman-Yassky E, de Bruin-Weller M, et al.: Conjunctivitis in dupilumab clinical trials. Br J Dermatol 2019;181:459-73.
- 21. Liberman P, Shifera AS, Berkenstock M: Dupilumab-associated conjunctivitis in patients with atopic dermatitis. Cornea 2020;39:784-6.
- 22. Levine RM, Tattersall IW, Gaudio PA, King BA: Cicatrizing blepharoconjunctivitis occurring during dupilumab treatment and a proposed algorithm for its management. JAMA Dermatol 2018;154:1485-6
| APA | YAŞAR G, BİLGİÇ A, Yilmaz E (2022). Dupilumab for atopic dermatitis treatment: A single-center retrospective study. , 12 - 16. 0.4274/turkderm.galenos.2021.36604 |
| Chicago | YAŞAR Gülbin,BİLGİÇ Aslı,Yilmaz Ertan Dupilumab for atopic dermatitis treatment: A single-center retrospective study. (2022): 12 - 16. 0.4274/turkderm.galenos.2021.36604 |
| MLA | YAŞAR Gülbin,BİLGİÇ Aslı,Yilmaz Ertan Dupilumab for atopic dermatitis treatment: A single-center retrospective study. , 2022, ss.12 - 16. 0.4274/turkderm.galenos.2021.36604 |
| AMA | YAŞAR G,BİLGİÇ A,Yilmaz E Dupilumab for atopic dermatitis treatment: A single-center retrospective study. . 2022; 12 - 16. 0.4274/turkderm.galenos.2021.36604 |
| Vancouver | YAŞAR G,BİLGİÇ A,Yilmaz E Dupilumab for atopic dermatitis treatment: A single-center retrospective study. . 2022; 12 - 16. 0.4274/turkderm.galenos.2021.36604 |
| IEEE | YAŞAR G,BİLGİÇ A,Yilmaz E "Dupilumab for atopic dermatitis treatment: A single-center retrospective study." , ss.12 - 16, 2022. 0.4274/turkderm.galenos.2021.36604 |
| ISNAD | YAŞAR, Gülbin vd. "Dupilumab for atopic dermatitis treatment: A single-center retrospective study". (2022), 12-16. https://doi.org/0.4274/turkderm.galenos.2021.36604 |
| APA | YAŞAR G, BİLGİÇ A, Yilmaz E (2022). Dupilumab for atopic dermatitis treatment: A single-center retrospective study. Türkderm Türk deri hastalıkları ve frengi arşivi, 56(1), 12 - 16. 0.4274/turkderm.galenos.2021.36604 |
| Chicago | YAŞAR Gülbin,BİLGİÇ Aslı,Yilmaz Ertan Dupilumab for atopic dermatitis treatment: A single-center retrospective study. Türkderm Türk deri hastalıkları ve frengi arşivi 56, no.1 (2022): 12 - 16. 0.4274/turkderm.galenos.2021.36604 |
| MLA | YAŞAR Gülbin,BİLGİÇ Aslı,Yilmaz Ertan Dupilumab for atopic dermatitis treatment: A single-center retrospective study. Türkderm Türk deri hastalıkları ve frengi arşivi, vol.56, no.1, 2022, ss.12 - 16. 0.4274/turkderm.galenos.2021.36604 |
| AMA | YAŞAR G,BİLGİÇ A,Yilmaz E Dupilumab for atopic dermatitis treatment: A single-center retrospective study. Türkderm Türk deri hastalıkları ve frengi arşivi. 2022; 56(1): 12 - 16. 0.4274/turkderm.galenos.2021.36604 |
| Vancouver | YAŞAR G,BİLGİÇ A,Yilmaz E Dupilumab for atopic dermatitis treatment: A single-center retrospective study. Türkderm Türk deri hastalıkları ve frengi arşivi. 2022; 56(1): 12 - 16. 0.4274/turkderm.galenos.2021.36604 |
| IEEE | YAŞAR G,BİLGİÇ A,Yilmaz E "Dupilumab for atopic dermatitis treatment: A single-center retrospective study." Türkderm Türk deri hastalıkları ve frengi arşivi, 56, ss.12 - 16, 2022. 0.4274/turkderm.galenos.2021.36604 |
| ISNAD | YAŞAR, Gülbin vd. "Dupilumab for atopic dermatitis treatment: A single-center retrospective study". Türkderm Türk deri hastalıkları ve frengi arşivi 56/1 (2022), 12-16. https://doi.org/0.4274/turkderm.galenos.2021.36604 |
